Home » Stocks » Vir Biotechnology

Vir Biotechnology, Inc. (VIR)

Stock Price: $41.02 USD 0.70 (1.74%)
Updated Jul 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.84B
Revenue (ttm) 10.15M
Net Income (ttm) n/a
Shares Out 117.90M
EPS (ttm) -14.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 6, 2020
Last Price $41.02
Previous Close $40.32
Change ($) 0.70
Change (%) 1.74%
Day's Open 38.80
Day's Range 38.72 - 41.38
Day's Volume 992,997
52-Week Range 11.65 - 75.00

More Stats

Market Cap 4.84B
Enterprise Value 4.49B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 117.90M
Float 50.32M
EPS (basic) n/a
EPS (diluted) -14.64
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.79M
Short Ratio 1.67
Short % of Float 5.09%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 476.58
PB Ratio 13.98
Revenue 10.15M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 351.18M
Net Cash / Share 2.98
Gross Margin -1,330.12%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -28.60%
ROE -87.32%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 2
Overweight 0
Hold 1
Underweight 1
Sell 1

Analyst Consensus: Overweight

Price Target

(-20.77% downside)
Current: 41.02
Target: 32.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-24.16%293.94%-
Gross Profit8.0910.672.71
Operating Income-178-119-81.50
Net Income-175-116-69.85
Shares Outstanding30.357.672.15
Earnings Per Share-5.76-15.12-32.45
Operating Cash Flow-130-94.10-66.38
Capital Expenditures-8.94-8.17-2.74
Free Cash Flow-139-102-69.12
Cash & Equivalents390109188
Net Cash / Debt390109188
Book Value424-179-68.92
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vir Biotechnology, Inc.
Country United States
Employees 237
CEO George A. Scangos

Stock Information

Ticker Symbol VIR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VIR


Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.